<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(9)</volume><submitter>Tian K</submitter><pubmed_abstract>Numerous viral outbreaks have threatened us throughout history. Here, we demonstrated a nucleic acid-based antiviral strategy named AntiV-SGN. Unlike those CRISPR-mediated methods, AntiV-SGN has advantages of no targets' sequence limitation, such as protospacer adjacent motif (PAM) or protospacer flanking sequence (PFS), being universal for both DNA and RNA viruses. AntiV-SGN was composed of a FEN1 protein and specific hpDNAs targeting viruses' nucleic acid. Its antiviral ability was tested on SARS-CoV-2 and HBV respectively. Reporter assays in human cells first illustrated the feasibility of AntiV-SGN. Then, it was verified that AntiV-SGN destroyed about 50% of live RNAs of SARS-CoV-2 in Vero cells and 90% cccDNA of HBV in HepG2.2.15 cells. It was also able to remove viral DNA integrated </pubmed_abstract><journal>Microbial biotechnology</journal><pagination>2488-2501</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9437879</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>AntiV-SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation.</pubmed_title><pmcid>PMC9437879</pmcid><pubmed_authors>Tian K</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Qi Z</pubmed_authors><pubmed_authors>Zhu F</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Qiang H</pubmed_authors><pubmed_authors>Zhou G</pubmed_authors><pubmed_authors>Chi Y</pubmed_authors><pubmed_authors>Guo Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>AntiV-SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation.</name><description>Numerous viral outbreaks have threatened us throughout history. Here, we demonstrated a nucleic acid-based antiviral strategy named AntiV-SGN. Unlike those CRISPR-mediated methods, AntiV-SGN has advantages of no targets' sequence limitation, such as protospacer adjacent motif (PAM) or protospacer flanking sequence (PFS), being universal for both DNA and RNA viruses. AntiV-SGN was composed of a FEN1 protein and specific hpDNAs targeting viruses' nucleic acid. Its antiviral ability was tested on SARS-CoV-2 and HBV respectively. Reporter assays in human cells first illustrated the feasibility of AntiV-SGN. Then, it was verified that AntiV-SGN destroyed about 50% of live RNAs of SARS-CoV-2 in Vero cells and 90% cccDNA of HBV in HepG2.2.15 cells. It was also able to remove viral DNA integrated </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-18T22:42:22.657Z</modification><creation>2025-04-07T10:29:38.501Z</creation></dates><accession>S-EPMC9437879</accession><cross_references><pubmed>35611874</pubmed><doi>10.1111/1751-7915.14076</doi></cross_references></HashMap>